Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CASTLE BIOSCIENCES INCCSTL · Entity 359 | Director | May 28, 2026 | June 01, 2026 |
| EXACT SCIENCES CORPEXAS · Entity 56619 | General Manager - Diagnostics | February 19, 2020 | February 21, 2020 |
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | Director | July 29, 2026 | July 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CASTLE BIOSCIENCES INC
Report date May 28, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 11,766 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 11,766 · Balance 11,766 F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 28, 2027, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
F2: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 28, 2027, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant.
EXACT SCIENCES CORP
Report date February 19, 2020 · Filed February 21, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,128 |
Reported balance
After 2020-02-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-02-19 · Exercise / conversion · Acquired 3,934 · Balance 24,128 F1: Represents shares of common stock received upon exercise of a stock option award. |
| Common StockSEC Table I · non-derivative | Direct | 37,550 |
Reported balance
After 2020-02-19 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-02-19 · Exercise / conversion · Acquired 13,422 · Balance 37,550 F1: Represents shares of common stock received upon exercise of a stock option award. |
| Common StockSEC Table I · non-derivative | Direct | 10,194 |
Reported balance
After 2020-02-19 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2020-02-19 · Sale · Disposed 27,356 · Balance 10,194 F2: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan. F3: In addition to the shares of Common Stock reported on this Form 4, which total 10,194 shares, Mr. Cole also holds, in the aggregate, an additional 53,377 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.28 · Expires 2026-02-16 | Direct | 0 |
Reported balance
After 2020-02-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-19 · Exercise / conversion · Disposed 3,934 · Balance 0 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.91 · Expires 2027-01-31 | Direct | 0 |
Reported balance
After 2020-02-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-19 · Exercise / conversion · Disposed 13,422 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock received upon exercise of a stock option award.
F2: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan.
F3: In addition to the shares of Common Stock reported on this Form 4, which total 10,194 shares, Mr. Cole also holds, in the aggregate, an additional 53,377 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock.
Kiniksa Pharmaceuticals International, plc
Report date July 29, 2026 · Filed July 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 7,172 |
Ending reported balance
After 2026-07-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-29 · Sale · Disposed 3,673 · Balance 11,672 Row 2 · 2026-07-29 · Gift · Disposed 4,500 · Balance 7,172 F1: This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GENOMIC HEALTH INC
Report date November 08, 2019 · Filed November 14, 2019
Section 16 reporting ended · disclosed 2019-11-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHeld by the Cole Family Trust | 11,794 |
Reported balance
After 2019-11-08 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-11-08 · Disposition to issuer · Disposed 27,385 · Balance 11,794 F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences,Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $753,089 and 12,335 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Common StockSEC Table I · non-derivative | IndirectHeld by the Cole Family Trust | 0 |
Reported balance
After 2019-11-08 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-11-08 · Disposition to issuer · Disposed 11,794 · Balance 0 F2: Disposed of in connection with the Merger, whereby such Issuer resticted stock unit ("RSU") was assumed by Exact Sciences and converted into a corresponding award for 9,026 RSUs of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.05 · Expires 2023-01-31 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-08 · Disposition to issuer · Disposed 1,888 · Balance 0 F3: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $30,130, less applicable tax withholdings, and 493 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.84 · Expires 2024-01-28 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $296,215, less applicable tax withholdings, and 4,851 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $31.12 · Expires 2025-02-13 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-08 · Disposition to issuer · Disposed 55,000 · Balance 0 F5: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $808,254, less applicable tax withholdings, and 13,238 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $27.00 · Expires 2026-02-16 | Direct | 5,142 |
Reported balance
After 2019-11-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-08 · Disposition to issuer · Disposed 56,558 · Balance 5,142 F6: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $927,027, less applicable tax withholdings, and 15,184 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $27.00 · Expires 2026-02-16 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-08 · Disposition to issuer · Disposed 5,142 · Balance 0 F7: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 3,935 shares of Exact Sciences common stock with an exercise price of $35.28 per share. |
| Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $27.48 · Expires 2027-01-31 | Direct | 17,538 |
Reported balance
After 2019-11-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-11-08 · Disposition to issuer · Disposed 38,582 · Balance 17,538 F8: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $624,767 less applicable tax withholdings, and 10,233 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $27.48 · Expires 2027-01-31 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-11-08 · Disposition to issuer · Disposed 17,538 · Balance 0 F9: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 13,422 shares of Exact Sciences common stock with an exercise price of $35.91 per share. |
| Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $33.21 · Expires 2028-01-31 | Direct | 29,436 |
Reported balance
After 2019-11-08 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-11-08 · Disposition to issuer · Disposed 22,894 · Balance 29,436 F10: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $316,752, less applicable tax withholdings, and 5,188 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $33.21 · Expires 2028-01-31 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-11-08 · Disposition to issuer · Disposed 29,436 · Balance 0 F11: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 22,528 shares of Exact Sciences common stock with an exercise price of $43.40 per share. |
| Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $72.52 · Expires 2029-01-29 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-11-08 · Disposition to issuer · Disposed 27,740 · Balance 0 F12: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 21,230 shares of Exact Sciences common stock with an exercise price of $94.76 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences,Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $753,089 and 12,335 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F2: Disposed of in connection with the Merger, whereby such Issuer resticted stock unit ("RSU") was assumed by Exact Sciences and converted into a corresponding award for 9,026 RSUs of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F3: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $30,130, less applicable tax withholdings, and 493 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $296,215, less applicable tax withholdings, and 4,851 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F5: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $808,254, less applicable tax withholdings, and 13,238 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F6: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $927,027, less applicable tax withholdings, and 15,184 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F7: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 3,935 shares of Exact Sciences common stock with an exercise price of $35.28 per share.
F8: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $624,767 less applicable tax withholdings, and 10,233 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F9: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 13,422 shares of Exact Sciences common stock with an exercise price of $35.91 per share.
F10: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $316,752, less applicable tax withholdings, and 5,188 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F11: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 22,528 shares of Exact Sciences common stock with an exercise price of $43.40 per share.
F12: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 21,230 shares of Exact Sciences common stock with an exercise price of $94.76 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2026 Filed Jul 31, 2026 20:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GiftClass A Ordinary Share | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001337798-26-000004 · form4-07312026_080745.xml · nonDerivative · entry 2 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,172 F1 · kind: This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund. Read SEC document |
| July 29, 2026 Filed Jul 31, 2026 20:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 3,673 | $81.43 | $299,092.39 |
DisclosureSEC source: 0001337798-26-000004 · form4-07312026_080745.xml · nonDerivative · entry 1 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,672 Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 2,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001337798-26-000002 · form4-06022026_080647.xml · derivative · entry 4 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 2,799 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs. F4 · derivative.expiration_date: The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 2,026 | $0.00 | $0.00 |
DisclosureSEC source: 0001337798-26-000002 · form4-06022026_080647.xml · derivative · entry 3 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,026 Underlying: Class A Ordinary Shares · 2,026 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. F3 · derivative.expiration_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 12,158 | $0.00 Strike: $48.38 | $0.00 |
DisclosureSEC source: 0001337798-26-000002 · form4-06022026_080647.xml · derivative · entry 2 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,158 Underlying: Class A Ordinary Shares · 12,158 shares Expires 2036-05-28 F2 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,799 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001337798-26-000002 · form4-06022026_080647.xml · nonDerivative · entry 1 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:43 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantRestricted Stock Units · Derivative | 11,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-26-000013 · wk-form4_1780346592.xml · derivative · entry 1 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,766 Underlying: Common Stock · 11,766 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 28, 2027, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant. F2 · derivative.expiration_date: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 28, 2027, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant. Read SEC document |
| May 22, 2026 Filed May 27, 2026 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 13,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-26-000011 · wk-form4_1779913247.xml · derivative · entry 2 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 22, 2026, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant. F2 · derivative.expiration_date: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 22, 2026, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant. Read SEC document |
| May 22, 2026 Filed May 27, 2026 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 13,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001447362-26-000011 · wk-form4_1779913247.xml · nonDerivative · entry 1 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:12 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 4,748 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001447362-26-000008 · wk-form4_1773087160.xml · derivative · entry 4 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 4,748 shares Expires 2029-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:12 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,655 | $28.51 | $75,694.05 |
DisclosureSEC source: 0001447362-26-000008 · wk-form4_1773087160.xml · nonDerivative · entry 3 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,309 F2 · price: This transaction was executed in multiple trades at prices ranging from $28.47 to $28.57, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:12 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,748 | $28.44 | $135,033.12 |
DisclosureSEC source: 0001447362-26-000008 · wk-form4_1773087160.xml · nonDerivative · entry 2 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,964 F1 · price: This transaction was executed in multiple trades at prices ranging from $28.39 to $28.51, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:12 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 4,748 | $3.38 | $16,048.24 |
DisclosureSEC source: 0001447362-26-000008 · wk-form4_1773087160.xml · nonDerivative · entry 1 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2025 Filed Jun 5, 2025 21:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 3,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015805 · form4-06052025_090634.xml · derivative · entry 4 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 3,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vested in a single installment on June 5, 2025; there was no expiration date for the RSUs. F4 · derivative.expiration_date: The RSUs vested in a single installment on June 5, 2025; there was no expiration date for the RSUs. Read SEC document |
| June 05, 2025 Filed Jun 5, 2025 21:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 3,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-015805 · form4-06052025_090634.xml · nonDerivative · entry 1 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 2,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015805 · form4-06052025_090634.xml · derivative · entry 3 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,799 Underlying: Class A Ordinary Shares · 2,799 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025. F3 · derivative.expiration_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 16,798 | $0.00 Strike: $29.11 | $0.00 |
DisclosureSEC source: 0001415889-25-015805 · form4-06052025_090634.xml · derivative · entry 2 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,798 Underlying: Class A Ordinary Shares · 16,798 shares Expires 2035-06-02 F2 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025. Read SEC document |
| May 22, 2025 Filed May 23, 2025 21:01 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantRestricted Stock Units · Derivative | 13,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-25-000087 · wk-form4_1748034070.xml · derivative · entry 3 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,667 Underlying: Common Stock · 13,667 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 22, 2026, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant. F3 · derivative.expiration_date: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 22, 2026, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant. Read SEC document |
| May 21, 2025 Filed May 23, 2025 21:01 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 8,673 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-25-000087 · wk-form4_1748034070.xml · derivative · entry 2 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,673 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 23, 2025, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant. F2 · derivative.expiration_date: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 23, 2025, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant. Read SEC document |
| May 21, 2025 Filed May 23, 2025 21:01 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 8,673 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001447362-25-000087 · wk-form4_1748034070.xml · nonDerivative · entry 1 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 4,373 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016009 · form4-06072024_080618.xml · derivative · entry 4 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 4,373 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F4 · derivative.exercise_date: The RSUs vested in a single installment on June 6, 2024; there was no expiration date for the RSUs. F4 · derivative.expiration_date: The RSUs vested in a single installment on June 6, 2024; there was no expiration date for the RSUs. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 4,373 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-016009 · form4-06072024_080618.xml · nonDerivative · entry 1 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 3,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016009 · form4-06072024_080618.xml · derivative · entry 3 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,173 Underlying: Class A Common Shares · 3,173 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary date of the grant, June 5, 2024. F3 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary date of the grant, June 5, 2024. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 19,040 | $0.00 Strike: $19.71 | $0.00 |
DisclosureSEC source: 0001415889-24-016009 · form4-06072024_080618.xml · derivative · entry 2 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,040 Underlying: Class A Common Shares · 19,040 shares Expires 2034-06-04 F2 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant. The date of the grant is June 5, 2024. Read SEC document |
| May 25, 2024 Filed May 29, 2024 20:43 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 8,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-24-000094 · wk-form4_1717015375.xml · derivative · entry 2 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,636 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vested in full on the one-year anniversary of the date of grant on May 25, 2024. F2 · derivative.expiration_date: The RSUs vested in full on the one-year anniversary of the date of grant on May 25, 2024. Read SEC document |
| May 25, 2024 Filed May 29, 2024 20:43 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 8,636 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001447362-24-000094 · wk-form4_1717015375.xml · nonDerivative · entry 1 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 23, 2024 Filed May 28, 2024 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantRestricted Stock Units · Derivative | 8,673 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-24-000076 · wk-form4_1716926801.xml · derivative · entry 1 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,673 Underlying: Common Stock · 8,673 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSU's vest in full on the one-year anniversary of the date of grant on May 23, 2025. F2 · derivative.expiration_date: The RSU's vest in full on the one-year anniversary of the date of grant on May 23, 2025. Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 20:15 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-010560 · form4-07032023_040703.xml · derivative · entry 2 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs. Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 20:15 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-010560 · form4-07032023_040703.xml · nonDerivative · entry 1 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 4,373 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009424 · form4-06082023_080641.xml · derivative · entry 2 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,373 Underlying: Class A Common Shares · 4,373 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023. F3 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 26,236 | $0.00 Strike: $15.19 | $0.00 |
DisclosureSEC source: 0001415889-23-009424 · form4-06082023_080641.xml · derivative · entry 1 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,236 Underlying: Class A Common Shares · 26,236 shares Expires 2033-06-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant. The date of the grant is June 6, 2023. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 20:40 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 3,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-23-000105 · wk-form4_1686084005.xml · derivative · entry 2 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,825 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vested in full on the one-year anniversary of the date of grant on June 2, 2023. F2 · derivative.expiration_date: The RSUs vested in full on the one-year anniversary of the date of grant on June 2, 2023. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 20:40 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 3,825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001447362-23-000105 · wk-form4_1686084005.xml · nonDerivative · entry 1 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 25, 2023 Filed May 30, 2023 21:48 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantRestricted Stock Units · Derivative | 8,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-23-000086 · wk-form4_1685483321.xml · derivative · entry 1 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,636 Underlying: Common Stock · 8,636 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest in full on the one-year anniversary of the date of grant on May 25, 2024. F2 · derivative.expiration_date: The RSUs vest in full on the one-year anniversary of the date of grant on May 25, 2024. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 20:17 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007103 · form4-06302022_010640.xml · derivative · entry 2 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Class A Common Shares · 5,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary of the date of grant, June 29, 2022. F3 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary of the date of grant, June 29, 2022. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 20:17 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 30,000 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001415889-22-007103 · form4-06302022_010640.xml · derivative · entry 1 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Class A Common Shares · 30,000 shares Expires 2032-06-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 29, 2022. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 830 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-22-000117 · wf-form4_165516151693035.xml · derivative · entry 2 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 830 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vested in full on the one-year anniversary of the date of grant on June 10, 2022. F2 · derivative.expiration_date: The RSUs vested in full on the one-year anniversary of the date of grant on June 10, 2022. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 830 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-22-000117 · wf-form4_165516151693035.xml · nonDerivative · entry 1 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 23:13 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantRestricted Stock Units · Derivative | 3,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-22-000100 · wf-form4_165455722481109.xml · derivative · entry 2 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,825 Underlying: Common Stock · 3,825 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest in full on the one-year anniversary of the date of grant on June 2, 2023. F2 · derivative.expiration_date: The RSUs vest in full on the one-year anniversary of the date of grant on June 2, 2023. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 23:13 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantStock option (right to buy) · Derivative | 7,647 | $0.00 Strike: $20.77 | $0.00 |
DisclosureSEC source: 0001447362-22-000100 · wf-form4_165455722481109.xml · derivative · entry 1 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,647 Underlying: Common Stock · 7,647 shares Expires 2032-06-01 Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 33,237 | $0.00 Strike: $14.33 | $0.00 |
DisclosureSEC source: 0001179110-21-007181 · edgar.xml · derivative · entry 1 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,237 Underlying: Class A Common Shares · 33,237 shares Expires 2031-06-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 29, 2021. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantRestricted Stock Units · Derivative | 830 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-21-000140 · wf-form4_162370255122954.xml · derivative · entry 2 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830 Underlying: Common Stock · 830 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest in full on the one-year anniversary of the date of grant on June 10, 2022. F2 · derivative.expiration_date: The RSUs vest in full on the one-year anniversary of the date of grant on June 10, 2022. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantStock option (right to buy) · Derivative | 3,379 | $0.00 Strike: $71.22 | $0.00 |
DisclosureSEC source: 0001447362-21-000140 · wf-form4_162370255122954.xml · derivative · entry 1 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,379 Underlying: Common Stock · 3,379 shares Expires 2031-06-09 Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 21:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 37,965 | $0.00 Strike: $20.09 | $0.00 |
DisclosureSEC source: 0001179110-20-008544 · edgar.xml · derivative · entry 1 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,965 Underlying: Class A Common Shares · 37,965 shares Expires 2030-07-26 F1 · derivative.exercise_date: The option vests and becomes exercisable as to one third of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a twenty-four month period thereafter. The vesting commencement date is July 27, 2020. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 16:28 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantStock option (right to buy) · Derivative | 8,000 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001447362-20-000113 · wf-form4_159163370513906.xml · derivative · entry 1 Cole G Bradley · CIK 0001337798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2030-06-03 Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 16:58 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionStock Option (right to buy) · Derivative | 13,422 | $0.00 Strike: $35.91 | $0.00 |
DisclosureSEC source: 0001209191-20-011595 · doc4.xml · derivative · entry 5 Cole G Bradley · CIK 0001337798 · General Manager - Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,422 shares Expires 2027-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 16:58 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionStock Option (right to buy) · Derivative | 3,934 | $0.00 Strike: $35.28 | $0.00 |
DisclosureSEC source: 0001209191-20-011595 · doc4.xml · derivative · entry 4 Cole G Bradley · CIK 0001337798 · General Manager - Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,934 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 16:58 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 27,356 | $100.00 | $2,735,600.00 |
DisclosureSEC source: 0001209191-20-011595 · doc4.xml · nonDerivative · entry 3 Cole G Bradley · CIK 0001337798 · General Manager - Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,194 F2 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 10,194 shares, Mr. Cole also holds, in the aggregate, an additional 53,377 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 16:58 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 13,422 | $35.91 | $481,984.02 |
DisclosureSEC source: 0001209191-20-011595 · doc4.xml · nonDerivative · entry 2 Cole G Bradley · CIK 0001337798 · General Manager - Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 16:58 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 3,934 | $35.28 | $138,791.52 |
DisclosureSEC source: 0001209191-20-011595 · doc4.xml · nonDerivative · entry 1 Cole G Bradley · CIK 0001337798 · General Manager - Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.